1. Home
  2. CTMX vs VSTM Comparison

CTMX vs VSTM Comparison

Compare CTMX & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$2.78

Market Cap

716.9M

Sector

Health Care

ML Signal

HOLD

VSTM

Verastem Inc.

HOLD

Current Price

$7.52

Market Cap

731.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTMX
VSTM
Founded
2008
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
716.9M
731.8M
IPO Year
2015
2011

Fundamental Metrics

Financial Performance
Metric
CTMX
VSTM
Price
$2.78
$7.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
7
Target Price
$12.10
$16.50
AVG Volume (30 Days)
3.6M
2.0M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.49
EPS
N/A
N/A
Revenue
$76,201,000.00
$30,914,000.00
Revenue This Year
N/A
$282.64
Revenue Next Year
$7.61
$72.25
P/E Ratio
$22.58
N/A
Revenue Growth
N/A
209.14
52 Week Low
$1.98
$3.43
52 Week High
$8.21
$10.82

Technical Indicators

Market Signals
Indicator
CTMX
VSTM
Relative Strength Index (RSI) 33.01 55.75
Support Level N/A $6.68
Resistance Level $3.93 $7.86
Average True Range (ATR) 0.22 0.41
MACD -0.09 -0.09
Stochastic Oscillator 6.97 32.79

Price Performance

Historical Comparison
CTMX
VSTM

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Share on Social Networks: